intellia logo
  • Full-Spectrum Blog
  • Contact
  • Info
    • Overview
    • Leadership
    • Partners
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs
    & Pipeline
    • Intellia’s Full-Spectrum Approach
    • Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
  • Patients
    & Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare
    Professionals
  • Investors
    & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us

Doudna named foreign member of UK’s Royal Society

Info

  • Overview
  • Leadership
  • Partners

Healthcare Professionals

  • Overview

CRISPR/Cas9

  • What’s CRISPR/Cas9?
  • How CRISPR/Cas9 Works
  • Types of Edits
  • Glossary

Investors & Media

  • Overview
  • Press Releases
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

Programs & Pipeline

  • Intellia’s Full-Spectrum Approach
  • Pipeline
  • In Vivo Therapies
  • Ex Vivo Therapies

Careers

  • Life @ Intellia
  • Join Us

Patients & Families

  • Our Commitment
  • Clinical Trials
  • Community Perspectives & Resources
  • Expanded Access Policy

© Intellia Therapeutics, Inc. 2021

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.

Menu